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Abstract
Background: Evidence shows that the standard process for obtaining informed consent in clinical
trials can be inadequate, with study participants frequently not understanding even basic
information fundamental to giving informed consent. Patient decision aids are effective decision
support tools originally designed to help patients make difficult treatment or screening decisions.
We propose that incorporating decision aids into the informed consent process will improve the
extent to which participants make decisions that are informed and consistent with their
preferences. A mixed methods study will test this proposal.
Methods: Phase one of this project will involve assessment of a stratified random sample of 50
consent documents from recently completed investigator-initiated clinical trials, according to
existing standards for supporting good decision making. Phase two will involve interviews of a
purposive sample of 50 trial participants (10 participants from each of five different clinical areas)
about their experience of the informed consent process, and how it could be improved. In phase
three, we will convert consent forms for two completed clinical trials into decision aids and pilot
test these new tools using a user-centered design approach, an iterative development process
commonly employed in computer usability literature. In phase four, we will conduct a pilot
observational study comparing the new tools to standard consent forms, with potential recruits to
two hypothetical clinical trials. Outcomes will include knowledge of key aspects of the decision,
knowledge of the probabilities of different outcomes, decisional conflict, the hypothetical
participation decision, and qualitative impressions of the experience.
Discussion: This work will provide initial evidence about whether a patient decision aid can
improve the informed consent process. The larger goal of this work is to examine whether study
recruitment can be improved from (barely) informed consent based on disclosure-oriented
documents, towards a process of high-quality participant decision-making.
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Background
Informed consent is a cornerstone of ethical healthcare
research, and is a required component of virtually all clin-
ical studies conducted in modern institutions. The basic
principles of informed consent were first documented as
the Nuremberg Code [1] in response to Nazi war crimes.
Later, these principles were refined and expanded as part
of the World Medical Association's Declaration of Hel-
sinki [2] in 1964, and its subsequent updates [3]. These
fundamental documents, as well as substantial philo-
sophical, clinical, legal, and regulatory debate [4,5] have
led to a general consensus regarding key criteria for
informed consent, which include: the decision to partici-
pate in clinical research must be made voluntarily and free
from coercion; the decision-maker must be competent to
make the decision; full disclosure of relevant information
must be given; and the relevant information must be
understood by the decision-maker [4].
Recent work has identified a tension between the latter
two core criteria [6-8]. On the one hand, researchers, insti-
tutions, and industry sponsors seek to disclose all poten-
tially relevant information and to ensure that legal
disclosure requirements are clearly met. Such disclosure is
being implemented with increasingly long and compli-
cated patient materials [7]. On the other hand, there is
increasing evidence that the existing consent process often
leads to poor participant understanding. Examples
abound of participants not understanding even the most
basic components of the studies in which they are
involved [9-22], including participants not understanding
that they had been randomly assigned to treatment [23],
and participants believing that their treatment was already
proven effective [24]. To an extent, pressures to disclose
and to aid understanding can be opposed; to date, it
appears that pressures towards disclosure have been
stronger than those towards ensuring participant under-
standing [25,26].
While the practice of informed consent has emphasized
disclosure and increasing complexity, there is considera-
ble literature on how to improve knowledge and under-
standing when making tough health care decisions. It is
well known, for example, that simply providing clear
information does not ensure that good decisions will be
made. Many factors not directly related to the actual infor-
mation presented can affect decision-making. Irrational
and/or emotional factors can be important determinants
of patient decisions [27,28]. Misunderstanding or misin-
terpretation of even clearly presented information can
contribute to poor decisions [29,30]. Presenting the same
information in different ways can result in different deci-
sions, suggesting that how the information is presented,
as well as what is presented, is important [31-33]. Further-
more, psychological states such as feeling unsure or
unprepared correlate with decision quality [34,35]. To
facilitate high quality decision-making, information must
be presented in a way that reduces the likelihood of mis-
interpretation, reduces uncertainty, and increases a feeling
of being prepared for the decision [35,36].
Decision quality can be a difficult concept in situations
where there is no objectively correct answer. The treat-
ment decision literature [37,38] distinguishes between
two kinds of decisions. Effective care decisions are those
where clinical evidence suggests a course of action that has
a benefit/harm ratio superior to all other available
options. In such situations, a 'good' decision typically
involves choosing the most effective option. In contrast,
'preference-sensitive' decisions have no clinically correct
course of action, either because evidence on treatment
effectiveness is unavailable, or because the benefits and
harms of different treatments need to be evaluated in the
context of patient values. It is for these preference-sensi-
tive decisions where defining decision quality can be chal-
lenging. However, more than 20 years of work on the
issue points to three critical components: a knowledge of
the key aspects of the decision, accurate perceptions of the
probabilities of outcomes under the different options,
and a match between what outcomes patients value and
the treatment options they choose [37,39].
The decision to participate in a clinical trial is an excellent
example of a preference-sensitive decision. The pros and
cons associated with participation (including, but not
limited to, the benefits and harms of offered treatments)
are frequently not well known; this is the reason for con-
ducting the trial. As a result, decisions about whether to
participate depend entirely on how individuals value the
potential benefits (e.g., incentives, potential health bene-
fits, altruism) and harms (e.g., side effects, clinic visits,
travel) of participation. It is precisely for preference-sensi-
tive decisions like these that patient decision aids (DAs)
have been developed.
DAs are tools designed to help people make specific and
deliberative choices among options by providing, at a
minimum, information on the options and outcomes rel-
evant to the person's health status. They can also include
exercises to help people explicate choice predisposition,
preference for role in decision-making, and how they
value the different options [40]. DAs are intended to be
used prior to, and in conjunction with, decision-making
counselling sessions, and are thus consistent with the
notion that consent should involve a process, not just a
document.
The effectiveness of DAs has been tested extensively, with
over sixty trials completed or in progress [40]. DAs have
been shown to improve the quality of preference-sensitiveImplementation Science 2008, 3:38 http://www.implementationscience.com/content/3/1/38
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patient decisions, in comparison to both standard care
information documents and standard counselling strate-
gies [35,36,39,41,42]. Specifically, they reduce uncer-
tainty surrounding decisions (often termed decisional
conflict [40,43]), enhance knowledge of key aspects of the
decision and outcome probabilities [40,44,45], improve
satisfaction with choices made, and improve the likeli-
hood that selected treatments will be consistent with val-
ued outcomes [44,46]. We propose that similar benefits
might be attained when deciding whether to participate in
a clinical trial. Furthermore, the related findings that DAs
improve understanding, that improved understanding
can increase trial participation rates [47-50], and that DAs
can increase selection of underused treatment options
[51,52] lead to the intriguing possibility that DAs may
increase trial participation in situations where benefits
compare favourably to harms.
Patient DAs have a strong theoretical foundation in the
Ottawa Decision Support Framework [53,54], an evi-
dence-based framework informed by cognitive, social,
and organizational psychological theory, components of
which have been validated in at least twelve studies [54].
This framework guided the development of the Interna-
tional Patient Decision Aid Standards (IPDAS) [36]. These
standards were developed using an extensive evidence-
based consensus process that included input from
patients, practitioners, policy-makers, and decision sup-
port experts from fourteen countries worldwide. The
IPDAS standards describe detailed recommendations
about the content and delivery of information to facilitate
high quality decisions. These standards are often consist-
ent with, but sometimes more specific than, consent form
guidelines. For example, while consent form guidelines
require general information on benefits and harms of trial
participation, IPDAS standards necessitate consistent
denominators, time periods, and multiple (positive and
negative) frames for outcome probabilities [36,55-57].
Furthermore, the IPDAS criteria also describe other exer-
cises, such as requiring decision-makers to clarify which
outcomes (positive and negative) they value most (e.g.,
How important to you is an X% chance of improvement?
How important is a Y% chance of a side effect?). Such
exercises are commonly used in the patient DA literature,
but rarely in the context of informed consent documents.
The decision support literature is increasingly focused on
the development of computer-based (i.e., 'online') deci-
sion aids. For information producers, the benefits of pre-
senting DAs online include easy updating compared to
print media, and easy dissemination via the internet [55].
For patients, advantages include accessibility and the
potential for improved learning if multimedia tools are
employed correctly [58]. Multimedia approaches as a class
have met with limited success [36,48], but our prelimi-
nary research suggests that multimedia DAs can be effec-
tive when informed by a theoretical framework [59].
Therefore, the DAs developed for this study will be
designed for presentation online.
To summarize, we propose that many failures of the exist-
ing informed consent process stem from an inappropriate
focus on disclosure of information, rather than on facili-
tating high quality decision-making among potential
research participants. In order for the informed consent
process to allow both disclosure and understanding, inno-
vative ways of presenting increasingly complex informa-
tion to decision-makers are required. Patient DAs, which
have been shown to improve decision-making in other
contexts, may improve the quality of trial participation
decisions. The current study will investigate this issue.
Objectives
This study has four main objectives:
First, to examine whether consent forms of recently com-
pleted randomized controlled trials (RCTs) conform to
standards for promoting high quality decision-making.
Specifically, we hypothesize that there will be considera-
ble variation in adherence to existing standards, even
among a relatively homogeneous sample of consent
forms drawn from investigator-initiated health research
RCTs, and that many consent forms will lack key compo-
nents necessary to facilitate high quality decision-making,
as indicated by existing standards.
Second, to learn about the experience of trial recruitment
from participants. Specifically, we will interview trial par-
ticipants about: how they were recruited to participate in
the trial; what factors they considered when deciding
whether to participate; their impressions and reported use
of any decision support materials provided; suggestions
about how the recruitment process might have been
improved; and overall impressions of trial participation.
Third, to employ a treatment DA template and user testing
via the user-centered design (UCD) approach to develop
a DA for people deciding whether to participate in a clin-
ical trial. Specifically, we hypothesize that a template
designed to inform development of patient DAs can be
effectively used to develop a DA about whether to partici-
pate in a clinical trial, and that DA development via UCD
can result in a DA that meets previously determined usa-
bility goals
Fourth, to test whether trial participation decisions based
on a user-tested patient DA (as opposed to a standard con-
sent form) will result in measurable differences in deci-
sion quality among hypothetical candidates for clinical
trials. Specifically, we hypothesize that people using a DAImplementation Science 2008, 3:38 http://www.implementationscience.com/content/3/1/38
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will be less uncertain about the decision [60-63]; better
remember the key aspects of the decision [45,64-71]; bet-
ter understand probabilities of key outcomes
[44,45,63,72-74]; show a higher correlation between out-
comes valued and choice made [40,44,46]; and, be more
likely to participate in the clinical trial [47,51,52,75].
Methods
Objective One: comparing consent forms to standards
Before developing a tool to help people decide whether to
participate in a clinical trial, it will be important to inves-
tigate the effectiveness of the current process. Objective
one will examine how well existing consent forms con-
form to empirically developed standards for promoting
high quality decisions.
The primary tool for this assessment will be a checklist
recently developed as part of the IPDAS [36]. Designed by
an international collaboration of experts on patient deci-
sion-making, this checklist includes 74 criteria from 12
quality domains; each of these criterion are considered
important for helping patients make difficult decisions
about treatment or screening. The IPDAS criteria overlap
with guidelines for informed consent documents (e.g., use
of plain language, reading level requirements, disclosure
of conflicts of interest, presenting both positive and nega-
tive outcomes associated with the different options). As
such, evaluating consent forms using this checklist will
also assess requirements laid out in consent form guide-
lines. For completeness, consent form recommendations
from other resources (e.g., U.S. National Cancer Institute,
National Cancer Institute of Canada, Tri-Council Policy
Statement [76,77]) will be examined and any identified
missing items will be appended to the checklist.
We will then assess a random sample of consent forms
from approved investigator-initiated trials completed
within the last six to 24 months at two institutions. The
random sample of clinical trials will be drawn from local
research ethics boards (REB) databases. Although these
databases contain information on all institution-specific
research projects, only non-industry studies labelled as
clinical trials involving adults will be eligible for inclu-
sion. Principal investigators of included studies will be
contacted directly for consent forms and assured that
identifying information (e.g., investigator and proprietary
drug names) will be removed before assessment. They will
be informed that results will be reported in aggregate,
meaning that individual studies will not be identified.
Principal investigators will also be asked for information
regarding overall enrolment rates; this should be known
since the sample of consent forms will be limited to stud-
ies completed within the last six to 24 months. If consent
forms for any of the target trials cannot be obtained, a
replacement study will be randomly selected from the
same review board database.
Study investigators who are approached to provide con-
sent material for this study may feel pressured to comply
because some of the authors are members of the local
REBs to which they may later submit protocols. An analo-
gous situation is common in clinical research, where phy-
sician-investigators recruit their patients into their own
studies. In that situation, recruitment materials com-
monly include information designed to reassure patients
that their care will not be affected by their decision to
accept or decline trial participation. Similarly, we will
reassure investigators that subsequent REB reviews will be
unaffected by their decision to participate in our study.
Furthermore, no investigator will review consent materi-
als until all identifying information has been redacted
from the documents. One investigator's name (RS) will be
left off all Ottawa recruitment letters; it was felt his name
may carry particular weight as he is the chair of the Ottawa
REB. Furthermore, we will ensure that RS does not review
any Ottawa consent materials, even after redaction.
A research coordinator and graduate student will be desig-
nated as coders and asked to rate all target consent forms
with respect to the IPDAS checklist, using a Yes (2), Partly
(1) and No (0) response scale for each criterion. For each
consent form, the coders will also extract several descrip-
tive factors that will later become the focus of post hoc
exploratory analyses. For example, each study will be
coded according to medical discipline (e.g., oncology),
and trial phase (e.g., phase one, phase two). Exploratory
analyses will then be used to look for correlations
between consent form quality and these descriptive fac-
tors, as well as the relation between quality and true
recruitment rate.
Sample size and analyses
Consent forms will be randomly selected (25 from each
institution) for application of the standards checklist.
Assuming that compliance with 60% of the IPDAS items
suggests a reasonable level of compliance, a sample of fifty
consent forms allows for the detection of an overall com-
pliance of 60% (30 of 50) with 95% confidence intervals
of ± 15% [78]. This sample size will allow us to quantify
the certainty of our estimates of the overall compliance
with IPDAS criterion in the larger population of consent
forms in the two databases.
Although the IPDAS checklist was developed according to
a rigorous Delphi methodology, this document has not
yet been validated as an assessment tool [36]. As a result,
the investigator team will first 'pilot' the rating of several
consent forms, thereby evaluating the checklist for over-
lapping, unclear, or missing items. These piloted consentImplementation Science 2008, 3:38 http://www.implementationscience.com/content/3/1/38
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forms will come from a database of publicly accessible
consent documents already in the possession of the
authors [79]. Once the items in the checklist have been
agreed upon, the investigator team will train the two cod-
ers using these same pilot consent forms. This training
will proceed until the consistency of coder agreement
exceeds 80% on various components of the checklist.
While coding the target consent forms, the two coders will
resolve disagreements by consensus or confer with the
investigator team when there is uncertainty. Inter-rater
agreement for each item will be assessed using Kappa
scores [80,81]. Because the checklist has not been vali-
dated overall as a scale of consent form quality, we will
not compute overall assessment scores, but instead only
examine descriptively the presence or absence of specific
criteria.
Descriptive analyses will be used to evaluate the number
and variation of checklist items present across the differ-
ent consent forms (hypothesis one). Also, descriptive
analyses will be used to identify which specific IPDAS
components are more or less likely to be included in con-
sent forms (hypothesis two). Further post hoc exploratory
analyses will examine whether consent forms from oncol-
ogy trials (an area where a significant work on consent
form ethics has been conducted) include more compo-
nents conducive to good decision-making than trials from
other areas, and determine the relationship between con-
sent form quality, as indicated by items on the IPDAS
checklist, and true enrolment rates.
Objective Two: interviews of trial participants
Objective one seeks to assess the current practice of trial
recruitment by evaluating existing written materials. How-
ever, studying trial recruitment should not be limited to
the written materials; other factors, such as consultation
with study personnel, often play an important role in this
process. Despite attempts to improve the informed con-
sent process [48], relatively few studies have described the
experiences of those individuals who must understand the
complex information presented in consent documents;
those that have focus on specific clinical areas [7]. Objec-
tive two will elicit the experiences of participants from a
variety of studies, to identify themes that may be broadly
applicable to improving the quality of participation deci-
sions.
We will interview recent recruits from a convenience sam-
ple of ongoing clinical trials at local institutions. Our aim
is not to document an exhaustive list of recruitment issues
for each study, but rather to elicit themes that are com-
mon across trial recruitment situations. The authors will
target eight to ten adult participants from multiple studies
in five disciplines (oncology, thrombosis, emergency
medicine, transfusion research, cardiology). Study investi-
gators will contact the lead investigators of the selected
RCTs and ask them to distribute recruitment letters to par-
ticipating patients, if ethical circumstances allow. Our
purposive sample will include both low- and high-risk
studies (as determined by the local REB records) from
each discipline, to elicit opinions about a range of studies.
Our phenomenological approach will involve semi-struc-
tured interviews approximately 45 minutes in length con-
sisting of questions focused on trial recruitment, provided
materials, decision-making, and how the overall process
could have been improved. Three pilot interviews will be
conducted to test the appropriateness and flow of the
interview guide; the interview questions will be modified
accordingly before proceeding with the remaining inter-
views. Participants will be prompted to provide clarifica-
tion and elicit more detail, and all interviews will be
recorded and transcribed. Participants will be offered $20
as a token of appreciation and to cover any attendant
costs. Qualitative analysis will use NUD*IST software,
applying the constant comparison method described by
Strauss and Corbin [82] to elicit clusters of meanings from
the narrative data that describe the experience of partici-
pants and inform the design of subsequent DAs.
Objective Three: iterative development of a decision aid
Considerable work has examined how best to present
complex information via computers [83-86]. Problems
with online information can be characterized in terms of
two dimensions: usability and usefulness [86]. Usability
refers to the ease with which specified users can locate and
interpret the information, while usefulness describes the
degree to which the right information is presented at the
right time. UCD is a qualitative, multi-stage procedure,
and is one of the most well studied, efficient, and cost-
effective methods for improving both the usability and
the usefulness of complex, online materials [87]. It is an
iterative process of design, evaluation, analysis, and re-
design intended to create a final product that meets prede-
termined usability goals (e.g., 90% of the time, patients
should be able to read and complete the DA in less than
30 minutes, and score 80% or better on a knowledge test
of the key aspects of the decision). This process has been
shown in a variety of contexts to improve user satisfaction
[88], reduce errors in navigation and the resulting confu-
sion [87,89], and to increase the efficiency with which the
information can be found [86]. However, this technique
has not yet been applied to decision support materials for
people making health care decisions.
We propose to employ UCD as a qualitative methodology
designed to optimize the IPDAS DA template for deci-
sions involving participation in clinical trials. This tem-
plate was developed for screening and treatment
decisions, where the benefits of using DAs have beenImplementation Science 2008, 3:38 http://www.implementationscience.com/content/3/1/38
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clearly demonstrated. However, neither the template nor
the generalized DA technology has been tested in the con-
text of clinical trial participation. As a result, some
detailed, qualitative pilot testing is required to examine
how a DA based on the IPDAS template mediates decision
making in this context.
We will develop DAs for two target studies from the set of
trials assessed in objective one. Although UCD testing is
labour intensive, developing two DAs instead of one will
help identify which issues can be generalized and which
issues are idiosyncratic to specific studies. The choice of
which two trials to focus on will be determined by two
main criteria. First, studies whose inclusion criteria are
extremely strict, or where the relevant population does
not exist locally, will be avoided to allow enough partici-
pants to be recruited for objective four. Second, if there is
significant variation in the extent to which consent forms
adhere to standards (objective one, hypothesis one), the
investigator group will choose one trial that meets rela-
tively few criteria and one that meets more. This selection
process will allow us in objective four to study whether a
DA only affords a benefit over poorly designed consent
forms. Note that analysis for this objective will be explor-
atory in nature, since any differences in the number of cri-
teria met will be confounded with clinical condition.
Risk information will be consistent for both consent
forms and DAs (i.e., the DA will not introduce any new
risk information). While both the DA literature and the
IPDAS criteria recommend providing specific numbers
associated with the risks of different outcomes, such spe-
cific outcome probabilities are often not available for clin-
ical trials. Therefore, for the purposes of this project,
specific outcome probabilities will not be included in the
DA if they are not provided in the associated consent
form. Instead, the DA will contain standardized descrip-
tors, such as those recommended by the National Cancer
Institute of Canada (e.g., common = > 200 per 1000, very
rare =< 1 per 1000) [90].
Data collection for this objective will consist of two
phases of qualitative UCD testing: expert testing and user
testing. Phase one will involve experts (three DA experts
and three content areas, drawn from the investigator team
and colleagues) working through the DA to ensure that all
information relevant to the decision is present. They will
examine the DA to ensure formatting conforms to basic
principles or 'heuristics' of good design (heuristic evalua-
tion [91]). These experts will also identify potential stum-
bling blocks in the material by working through the entire
tool; this technique is referred to as a 'cognitive walk-
through' [92].
Once the expert evaluations are complete, phase two will
subject the updated version of the DA to a series of 'user
tests' involving adult participants 'talking aloud' [93] as
they work through the tool. The user tests will be video-
taped and evaluated for user misunderstandings, expres-
sions of frustration or confusion, and the specific areas of
the DA where these occurred. These 'usability problems',
as well as items that multiple users identify as challenging,
will become target areas for improvements on subsequent
iterations. The DA will be revised after each iteration of
five or six participants [86]. This iterative approach pro-
vides (in the first iteration) baseline measures of user sat-
isfaction and performance (time required to read,
comprehension, misunderstandings), as well as (in later
iterations) the degree to which the current version of a DA
meets pre-specified usability goals. Each session will take
approximately 45 to 60 minutes, for which participants
will be offered $20 as a token of appreciation and to cover
any attendant costs.
Sample size and analyses
Participants in this phase of the study will be naïve volun-
teers age-matched to typical patients with the condition
discussed in the DA. Based on previous experience and the
usability testing literature [93], four to five iterations of
five to six participants each will be sufficient to meet the
usability goals described above (i.e., twenty to thirty par-
ticipants will be required).
Objective Four: prospective observational study
Objective four will compare the experiences of people
using consent forms and DAs to assist hypothetical deci-
sions about trial participation. This objective will consist
of a prospective observational study designed to collect
both qualitative and quantitative data relevant to whether
this approach warrants further evaluation with a pilot
RCT.
Participants will be naïve individuals who meet the inclu-
sion criteria of the target study, and thus could have been
approached to participate in the original study. However,
those who actually were approached to participate in the
target study, regardless of their decision to participate, will
be excluded from our study. In addition to the type of
decision tool (consent form, DA), the two consent forms
that were subjected to user testing from objective three
will be the focus of this study. Participants will be eligible
for our study if they speak English, are over 18 years of
age, and meet the inclusion criteria of one of the target
studies.
Potential participants that meet one of the two sets of
inclusion criteria will be approached to enrol in our study
(i.e., non-random allocation to target study), and stand-
ard consent will be obtained. Participants will workImplementation Science 2008, 3:38 http://www.implementationscience.com/content/3/1/38
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through one of the two decision support tools. Data will
first be collected on consent forms, then later for DAs. We
have chosen this approach for two reasons. First, by col-
lecting data for consent forms initially, we will not need
to wait until the end of DA user testing to begin data col-
lection for objective four. Participants may need to fit
strict inclusion criteria for the relevant studies chosen for
objective four; this approach adds flexibility to our time-
line. Second, we will incorporate information gleaned
from the consent form participants (particularly their
qualitative responses) to further improve the DA. This
approach sacrifices the experimental rigour of an RCT, but
adds a richness of qualitative and quantitative data that is
most likely to result in both a tool that maximally
improves the informed consent process, and in a better
understanding of what outcomes are affected by the newer
decision support tool.
After working through the decision support tool, partici-
pants will complete a paper-based questionnaire. This
questionnaire will include validated measures of con-
structs related to decision quality, as well as qualitative
questions about their impressions of recruitment process
and materials. Quantitative outcomes measured will
include decisional conflict [94], memory for key aspects
of the decision, knowledge of the probabilities of different
outcomes, values associated with different outcomes for
comparison with the participation choice, and participa-
tion choice. We will also measure satisfaction with the
decision support materials, satisfaction with the informed
consent process [49], and anticipated regret of key nega-
tive outcomes. In addition, participants will be asked to
make a hypothetical decision about whether or not they
would participate in the target trial (yes, no, unsure). Of
note, participants will not have access to the decision sup-
port materials when completing the questionnaire. At the
end of the session, participants will be provided with a
debriefing form, explaining the purpose of the study and
how their data will contribute to towards improving the
consent process. The entire session will take 45 to 60 min-
utes, for which participants will be offered $20 as a token
of appreciation and to cover any attendant costs.
Sample size and analyses
The sample size calculation was based on detecting differ-
ences on the continuous decisional conflict scale [43]. The
authors selected this scale as the primary outcome for this
analysis because it is considered a key correlate of good
decision quality and has been well validated in the context
of many treatment decisions. Sample size calculations
were carried out by simulation using the AOV function of
R statistical software [95]. We conducted a simulation
with 50,000 iterations, detecting a 10% difference on a
continuous outcome. Results of the simulation showed
that a sample size of 30 individuals per group, or 120 in
total, yields a proportion of rejecting the null when it is
true of 0.048 (i.e., alpha level is approximately 0.05),
while the proportion of incorrectly accepting the null
hypothesis is less than 0.01 (i.e., power is greater than
0.99).
Analyses for this study will consist of linear (for continu-
ous outcomes) and logistic regressions, with type of deci-
sion support (consent form/DA), target study, and their
interaction predicting the different outcomes. For exam-
ple, when predicting decisional conflict, a significant
effect of type of decision support will indicate whether
those making decisions on the basis of consent form and
DA differ in terms of how unsure they remain about the
decision. Similarly, a significant effect of target study will
demonstrate whether satisfaction was higher for one con-
dition regardless of type of decision support, and their
interaction will show whether the two effects are inde-
pendent. The collected demographic characteristics of
respondents (e.g., age, sex) will also be included as covari-
ates.
Hypotheses for this objective were principally derived
from literature on the effects of DAs on treatment deci-
sions, i.e., that they improve the quality of decision-mak-
ing. The authors hypothesize that using a DA will result in:
reduced indecision and decisional conflict
[39,40,45,61,62]; improved memory for key aspects of
the decision [64,96]; improved knowledge of key out-
come probabilities [40]; and a higher correlation between
self-identified important outcomes and the selected treat-
ment choice [40,97]. Literature has shown that DAs can
affect behavioural outcomes, such as increased use of
underused treatments [51,52], and that that confusion
arising from consent forms may contribute to non-partic-
ipation [48]. As a result, we further hypothesize that DAs
may increase participation in trials where risk/benefit
ratios are favourable.
Finally, we will collect and analyze the number and con-
tent of questions that potential participants ask after
working through the decision support materials. These
post-consent form discussions will not only serve to make
the consent process more representative of real world rec-
ommended practice [48], they will also serve as a valuable
data collection opportunity. The DA will explicitly ask
people to record any unanswered questions about the
associated trial, while encouraging systematic thinking
about the various possible outcomes. As a result, we
expect that more questions, and more detailed questions,
will stem from those working through the DA as opposed
to the consent form. The enrolment rates of the sample
consent participants will be compared to the reported trial
enrolment rates, to estimate how closely hypothetical
recruitment mimics real life situations.Implementation Science 2008, 3:38 http://www.implementationscience.com/content/3/1/38
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Limitations
A number of limitations of this study warrant considera-
tion. First, the development of a DA to better inform trial
participation decisions does not address all the ethical
concerns related to informed consent. It has also been
argued that the existing informed consent process lends
itself to problems by focusing on specific, isolated deci-
sions, rather than larger concepts such as overall auton-
omy of the individual (e.g., see Kukla [98]). While the
current approach does not directly address these larger
issues, we believe that the development of improved deci-
sion tools will serve such larger goals. For example,
improved decision tools will encourage thinking about
informed consent as a process rather than a discrete event.
Furthermore, DAs may elicit benefits beyond the immedi-
ate aims of this study by explicitly addressing issues such
as the balance between benefits and harms, and prompt-
ing potential participants to think about what further
information they require and their preferred role in deci-
sion-making [7]. Since memory for information presented
during the consent process can fade throughout participa-
tion [49], the DAs developed for this study will include a
take home one-page summary that can be used to period-
ically review key trial information. Future work, perhaps
involving a larger study examining the entire time course
of trial participation, will be required to consider these
larger ethical concerns.
Second, the IPDAS checklist used in objective one has not
been validated as an assessment tool. This checklist was
developed according to a modified Delphi method [99],
and constitutes the consensus of an international consor-
tium of experts on which items comprise high quality
decision support. Because the checklist has not been for-
mally validated, we decided to incorporate a pilot testing
phase designed to identify overlapping or problematic
items and describe item-specific results; an overall 'qual-
ity' score will not be computed. Future work should
involve formal psychometric analysis of the IPDAS check-
list as a measure of DA quality in treatment decisions, and
separately as an indicator of the ability to improve
informed consent.
Third, objectives three and four will make use of hypo-
thetical decision-makers rather than actual patients mak-
ing real world decisions. This characteristic is common in
the literature, but has been argued to adversely affect study
generalizability [48]. However, increasing evidence shows
that decision-making based on hypothetical, written sce-
narios is highly correlated with real world decisions
[100,101]. This study is designed to determine whether
incorporating DAs into real informed consent decisions is
worthwhile; as such, we felt that it would be inappropriate
to use actual patients until it is known whether DAs are at
least as effective as standard practice in assisting decision-
making. However, it may be that in this context, hypothet-
ical decisions are not predictive of actual decisions. This
issue will be addressed by examining the calibration of
hypothetical enrolment rates from objective four with
true enrolment rates collected in objective one. Determin-
ing the usefulness of DAs for true participation decisions
will be the subject of another study.
Fourth, objective four will compare online DAs to exist-
ing, paper-based consent forms, which are still the current
norm for most clinical trials. This comparison leaves open
the possibility that any observed variation could stem
from the difference in media (paper-based versus online)
rather than differences in the decision support tool itself
(consent form versus DA). However, a recent systematic
review of interventions designed to improve informed
consent documents showed that presenting the informa-
tion online is not enough to ensure better understanding,
and a meta analysis of all multimedia manipulations
showed a null effect on consent form knowledge [48]. As
a result, we expect that any response differences between
the two types of decision material will be primarily due to
variations in the support framework, rather than any
implicit advantage in the display medium.
Fifth, blinding, allocation concealment and randomiza-
tion for objective four are impossible or impractical, and
thus strong claims about the relative benefits of DAs ver-
sus consent forms cannot be made. The next step in this
research program will address this issue by comparing the
performance of DAs and consent forms in the context of a
real world RCT.
Sixth, this work will focus only on investigator-initiated
trials, and not industry-sponsored trials. Practical and
legal aspects of studying industry trials led us to limit our
samples for this project; however, this subgroup of trials is
clearly of interest and will be the subject of a separate
investigation.
Finally, examination of long term effects of the informed
consent process, such as dropout rates, satisfaction or
regret with participation in the trial, willingness to partic-
ipate in a similar trial, etc., will not be possible in this
short term project, and will be the subject of future work.
The current study will examine only immediate outcomes
that in the treatment decision literature are known to be
correlated with the longer term outcomes [102].
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